Relationship between SP142 PD-L1 Expression and ¹⁸F-FDG Uptake in Non-Small-Cell Lung Cancer

Table 3

The relationship between programmed death ligand-1 expression and clinicopathological characteristics of pulmonary squamous cell carcinoma.

Clinical factors	Total		PD-L1 expression				Univariate analysis
	No.	%	Negative		Positive		OR (95% CI)	value
	95	100.0	34	35.8%	61	64.2%
Age (y)							0.564 (0.24–1.34)	0.193
<64	42	44.2	12	28.6%	30	71.4%	Reference
≥64	53	55.8	22	41.5%	31	58.5%
Sex							0.89 (0.08–10.24)	0.928
Male	92	96.8	33	35.9%	59	64.1%	Reference
Female	3	3.2	1	33.3%	2	66.7%
Smoking history							2.27 (0.59–8.80)	0.234
Never	14	14.7	3	21.4%	11	78.6%
Former/current	81	85.3	31	38.3%	50	61.7%	Reference
Size (cm)							0.66 (0.28–1.53)	0.335
<4.2	51	53.7	16	31.4%	35	68.6%	Reference
≥4.2	44	46.3	18	40.9%	26	59.1%
Pathological stage							0.72 (0.42–1.21)	0.211
I	39	41.1	12	30.8%	27	69.2%
II	34	35.8	11	32.4%	23	67.6%
III	21	22.1	11	52.4%	10	47.6%
IV	1	1.1	0	0.0%	1	100.0%
T stage							0.92 (0.61–1.39)	0.696
T1	35	36.8	11	31.4%	24	68.6%
T2	30	31.6	12	40.0%	18	60.0%
T3	19	20.0	7	36.8%	12	63.2%
T4	11	11.6	4	36.4%	7	63.6%
Lymph node metastases							0.68 (0.27–1.72)	0.417
N0	69	72.6	23	33.3%	46	66.7%	Reference
N1/N2/N3	26	27.4	11	42.3%	15	57.7%
Metastatic								1.000
M0	94	98.9	34	36.2%	60	63.8%	Reference
M1	1	1.1	0	0.0%	1	100.0%
SUVmax							8.4 (1.83–38.53)	.006
<20.72	72	75.8	32	44.4%	40	55.6%
≥20.72	23	24.2	2	8.7%	21	91.3%
EGFR mutation status								0.999
Mutation	2	2.1	0	0.0%	2	100.0%	Reference
Wild type	93	97.9	34	36.6%	59	63.4%

PD-L1, programmed cell death ligand-1; SUVmax, maximum standardized uptake value; EGFR, epidermal growth factor receptor.